Skip to navigation Skip to content Skip to footer

Modified PvDBP-RII subdomain 3 for a polypeptide vaccine for Plasmodium vivax

Image from Licence Details: Modified PvDBP-RII subdomain 3 for a polypeptide vaccine for Plasmodium vivax

Applications: synthetic polypeptide, vaccination against Plasmodium vivax

Features	Benefits
Novel immunogen based on modified Duffy binding domain (DBP) of Plasmodium vivax, specifically subdomain 3 of the PvDBP-RII protein domain	Effectively target the reticulocyte invasion stage of Plasmodium vivax to prevent symptoms and malaria transmission
Structure-guided immunogen design, which modifications allows production of correctly folded form.	Modifications leading to immunogen allows effective production and scalability, hence effective vaccination.
Preclinical data demonstrates a more effective growth-inhibitory antibody repertoire compared to the current best PvDBP-RII immunogen	Ready to be tested in clinical trials Can be used for analysing antibody repertoire generated in response to vaccination or natural infection
Immunogen can be included in prophylaxis for Malaria by itself or in combination with other components as a multi-stage vaccine	Adaptability in vaccine program design

Patent pending & available for:

Licensing
Co-development

Request more information
about this technology

Back to Technologies Available

Sparks Background Image

Ready to get in touch?

Contact Us

Sparks Background Image

© Oxford University Innovation